Myriad Data at ASCO-GU Bolsters MRD, Prognostic Test Claims
Event summary
- Myriad Genetics presented six abstracts at the ASCO-GU 2026 conference, focusing on its Precise MRD, Prolaris, and MyRisk tests.
- Data from a meta-analysis of 14 studies (over 8,000 patients) supports the prognostic power of the Prolaris prostate cancer test, showing significance beyond clinical risk factors.
- MyRisk testing data suggest germline variant prevalence is consistent across Gleason score and NCCN risk groups, potentially broadening testing scope.
- Precise MRD demonstrated high sensitivity in detecting ctDNA at concentrations below 100 parts per million in genitourinary cancers.
- Presentations occurred February 26-28, 2026, at the Moscone West Conference Center in San Francisco.
The big picture
Myriad's presentation underscores the growing importance of molecular diagnostics in cancer treatment, particularly the shift towards earlier detection and personalized therapies. The data reinforces Myriad’s strategy of expanding its portfolio across the cancer care continuum, but also highlights the challenges of demonstrating clinical utility and securing reimbursement for these advanced tests. The company's ability to translate these findings into commercially viable products will be crucial for sustained growth.
What we're watching
- Clinical Adoption
- The pace at which clinicians integrate Precise MRD into standard treatment protocols will determine its revenue impact, particularly given the early-stage nature of the data presented.
- Regulatory Scrutiny
- Expanded MyRisk testing, as suggested by the data, could draw increased scrutiny from payers and regulators regarding cost-effectiveness and clinical utility.
- Competitive Landscape
- How competitors respond to Myriad’s MRD data and refine their own offerings will shape the long-term viability of Myriad’s position in the evolving molecular diagnostics market.
Related topics